Samil Pharm (KO:000520) — Market Cap & Net Worth
Market Cap & Net Worth: Samil Pharm (000520)
Samil Pharm (KO:000520) has a market capitalization of $100.85 Million (₩148.82 Billion) as of September 17, 2026. Listed on the KO stock exchange, this Korea-based company holds position #19238 globally and #944 in its home market, demonstrating a 11.62% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Samil Pharm's stock price ₩7010.00 by its total outstanding shares 21229653 (21.23 Million). Also see 000520 asset base for a full breakdown of the balance sheet.
Samil Pharm Market Cap History: 2015 to 2026
Samil Pharm's market capitalization history from 2015 to 2026. Data shows growth from $42.25 Million to $100.85 Million (8.98% CAGR). Also see 000520 cash flow conversion for how efficiently the company converts equity into cash flow.
Samil Pharm Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Samil Pharm's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 000520 share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
Samil Pharm's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $42.25 Million | $88.14 Billion | $588.37 Million | 0.00x | 0.07x |
| 2016 | $49.85 Million | $96.76 Billion | $886.60 Million | 0.00x | 0.06x |
| 2017 | $51.63 Million | $92.04 Billion | -$1.27 Billion | 0.00x | N/A |
| 2018 | $129.78 Million | $94.60 Billion | -$8.56 Billion | 0.00x | N/A |
| 2019 | $133.67 Million | $121.11 Billion | $786.26 Million | 0.00x | 0.17x |
| 2020 | $131.88 Million | $123.00 Billion | $1.34 Billion | 0.00x | 0.10x |
| 2021 | $107.93 Million | $134.25 Billion | -$5.35 Billion | 0.00x | N/A |
| 2022 | $112.22 Million | $179.68 Billion | -$28.29 Million | 0.00x | N/A |
| 2023 | $96.39 Million | $196.35 Billion | $1.66 Billion | 0.00x | 0.06x |
| 2024 | $189.19 Million | $219.70 Billion | -$5.63 Billion | 0.00x | N/A |
Competitor Companies of 000520 by Market Capitalization
Companies near Samil Pharm in the global market cap rankings as of September 17, 2026. Review Samil Pharm tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Samil Pharm by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Samil Pharm Historical Marketcap From 2015 to 2026
Between 2015 and today, Samil Pharm's market cap moved from $42.25 Million to $ 100.85 Million, with a yearly change of 8.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩100.85 Million | -27.66% |
| 2025 | ₩139.41 Million | -26.31% |
| 2024 | ₩189.19 Million | +96.27% |
| 2023 | ₩96.39 Million | -14.10% |
| 2022 | ₩112.22 Million | +3.97% |
| 2021 | ₩107.93 Million | -18.16% |
| 2020 | ₩131.88 Million | -1.34% |
| 2019 | ₩133.67 Million | +3.00% |
| 2018 | ₩129.78 Million | +151.35% |
| 2017 | ₩51.63 Million | +3.57% |
| 2016 | ₩49.85 Million | +17.98% |
| 2015 | ₩42.25 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Samil Pharm was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $100.85 Million USD |
| MoneyControl | $100.85 Million USD |
| MarketWatch | $100.85 Million USD |
| marketcap.company | $100.85 Million USD |
| Reuters | $100.85 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Samil Pharm
Samil Pharmaceutical Co.,Ltd engages in the manufacture and sale of indispensable medicines in South Korea. It offers hepatic, gastrointestinal, vasodilator, antithrombotic, respiratory, skeletal muscle relaxants, circulatory, neurological, antibiotics, metabolic, antihistamines, immunosuppressive, hormone, anti-tumor, urinary, and ophthalmic drugs, as well as antipyretic, analgesic, and anti-inf… Read more